TROG 98.03 - Prostate - Margin +ve Post-Prostatectomy

By w.paterson
15 August, 2021
0 Comments

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

23 October, 2024

New Cancer Australia grant supports TROG work

23 October 2024: TROG Cancer Research is thrilled to

15 October, 2024

Diversity, equity and inclusion at heart of TROG work

15 October 2024: TROG Cancer Research has made a

Join us to raise $20,000

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

TROG 98.04 – Liver Metastases

TROG 98.02/EFC3344 – Head & Neck/Tirapazamine (Phase II)

Related Post

New Cancer Australia grant supports TROG work

Diversity, equity and inclusion at heart of TROG work

Join us to raise $20,000

TROG 98.03 – Prostate – Margin +ve Post-Prostatectomy

Randomised Trial to Compare the Rates of Disease-Free Survival in Margine-Positive Patients After Radical Prostatectomy With or Without Adjuvant Post-Operative Radiotherapy

TROG 98.04 – Liver Metastases

TROG 98.02/EFC3344 – Head & Neck/Tirapazamine (Phase II)

Related Post

New Cancer Australia grant supports TROG work

Diversity, equity and inclusion at heart of TROG work

Join us to raise $20,000